Hémostase. Le point sur les nouveaux antithrombotiques
|Published in||Revue médicale suisse. 2010, vol. 6, no. 232, p. 109-112|
|Abstract||Update on new antithrombotic treatments Antithrombotic treatments are frequently prescribed in different clinical situations. Classical anticoagulants have some disadvantages. New anticoagulants have emerged recently. Fondaparinux is now prescribed for both prophylaxis and treatment of venous thromboembolism. Two drugs are particularly interesting: rivaroxaban and dabigatran. Concerning the new antiplatelet agents, many molecules such as prasugrel, ticagrelor, cangrelor, SCH530348 or terutroban have appeared recently. They are directed either to the P2Y12 receptor or to other original targets. Studies have shown an increased bleeding risk for some of them as well as unexpected side effects. In the next future, these new molecules could allow a more individualised prescription of antithrombotic agents.|
|Keywords||Anticoagulants/*pharmacology — Clinical Trials as Topic — Humans — Platelet Aggregation Inhibitors/*pharmacology — Thrombosis/*prevention & control|
This document has no fulltext available yet, but you can contact its author by using the form below.
|Research groups||Anticorps antiphospholipides (12)|
Geneva Platelet Group (13)
|BOEHLEN, Françoise et al. Hémostase. Le point sur les nouveaux antithrombotiques. In: Revue médicale suisse, 2010, vol. 6, n° 232, p. 109-112. https://archive-ouverte.unige.ch/unige:20437|